Columbus Circle Investors’s Teva Pharmaceuticals TEVA Stock Holding History

Columbus Circle Investors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-123,241	Closed	-$6.59M	–	292
2016 Q1	$6.59M	Sell	123,241 -411,815	-77%	-$24.2M	0.06%	204
2015 Q4	$35.1M	Buy	535,056 +34,797	+7%	+$2.15M	0.28%	86
2015 Q3	$28.2M	Buy	500,259 +161,694	+48%	+$10.5M	0.23%	96
2015 Q2	$20M	Sell	338,565 -113,539	-25%	-$7M	0.14%	170
2015 Q1	$28.2M	Sell	452,104 -365,746	-45%	-$21.3M	0.19%	117
2014 Q4	$47M	Buy	817,850 +240,734	+42%	+$13.4M	0.33%	76
2014 Q3	$31M	Sell	577,116 -237,003	-29%	-$12.6M	0.22%	106
2014 Q2	$42.7M	Buy	814,119 +150,051	+23%	+$7.67M	0.29%	94
2014 Q1	$35.1M	Buy	664,068 +379,098	+133%	+$17.5M	0.23%	111
2013 Q4	$11.4M	Buy	+284,970	New	+$11.2M	0.08%	210

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Columbus Circle Investors's TEVA Position: Q2 2016 in Review

Columbus Circle Investors sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 123,241 shares — an estimated $6.59M sold.

Columbus Circle Investors first reported a position in TEVA in Q4 2013 and held it in 10 quarters. The position peaked at $47M in Q4 2014. 812 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

Columbus Circle Investors reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Columbus Circle Investors sold 123,241 Teva Pharmaceuticals shares in Q2 2016, an estimated $6.59M.
Columbus Circle Investors first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 10 quarters.
Columbus Circle Investors's Teva Pharmaceuticals position peaked at $47M in Q4 2014.
812 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Columbus Circle Investors's 13F filing for Q2 2016, filed 2 Aug 2016.